English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/180689
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Identification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactions

AuthorsBarbero, Nekane; Fernández-Santamaría, Rubén; Mayorga, Cristobalina; Martín-Serrano, Ángela; Salas, María; Bogas, Gador; Nájera, Francisco; Pérez-Sala, Dolores ; Pérez-Inestrosa, Ezequiel; Fernández, Tahia; Montañez, M. I.; Torres, María J.
Clavulanic acid
Drug allergy
Immediate reactions
In vitro test
Issue Date4-Mar-2019
PublisherJohn Wiley & Sons
CitationAllergy (2019)
AbstractBACKGROUND: Selective reactions to clavulanic acid (CLV) account for around 30% of immediate reactions after administration of amoxicillin-CLV. Currently, no immunoassay is available for detecting specific IgE to CLV, and its specific recognition in patients with immediate reactions has only been demonstrated by basophil activation testing, however with suboptimal sensitivity. The lack of knowledge regarding the structure of the drug that remains bound to proteins (antigenic determinant) is hampering the development of in vitro diagnostics. We aimed to identify the antigenic determinants of CLV as well as to evaluate their specific IgE recognition and potential role for diagnosis.
METHODS: Based on complex CLV degradation mechanisms, we hypothesized the formation of two antigenic determinants for CLV, AD-I (N-protein, 3-oxopropanamide) and AD-II (N-protein, 3-aminopropanamide), and designed different synthetic analogs to each one. IgE recognition of these structures was evaluated in basophils from patients with selective reactions to CLV and tolerant subjects. In parallel, the CLV fragments bound to proteins were identified by proteomic approaches.
RESULTS: Two synthetic analogs of AD-I were found to activate basophils from allergic patients. This determinant was also detected bound to lysines 195 and 475 of CLV-treated human serum albumin. One of these analogs was able to activate basophils in 59% of patients whereas CLV only in 41%. Combining both results led to an increase in basophil activation in 69% of patients, and only in 12% of controls.
CONCLUSION: We have identified AD-I as one CLV antigenic determinant, which is the drug fragment that remains protein-bound.
Description12 p.-6 fig.-1 graf. abst.
Publisher version (URL)https://doi.org/10.1111/all.13761
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
restringido.pdfRestringido20,59 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.